Patents by Inventor Robert N. Sibley

Robert N. Sibley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
    Publication number: 20120040986
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: August 11, 2011
    Publication date: February 16, 2012
    Inventors: Bernd RIEDL, Jacques DUMAS, Uday KHIRE, Timothy B. LOWINGER, William J. SCOTT, Roger A. SMITH, Jill E. WOOD, Mary-Katherine MONAHAN, Reina NATERO, Joel RENICK, Robert N. SIBLEY
  • SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY
    Publication number: 20110263597
    Abstract: Methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using substituted pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R1 and R2 may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents.
    Type: Application
    Filed: July 7, 2011
    Publication date: October 27, 2011
    Applicant: Bayer HealthCare LLC
    Inventors: Jacques P. Dumas, Stephen James Boyer, Julie A. Dixon, Teddy Kite Joe, Harold C. E. Kluender, Wendy Lee, Dhanapalan Nagarathnam, Robert N. Sibley, Ning Su
  • Substituted pyridines and pyridazines with angiogenesis inhibiting activity
    Patent number: 7977333
    Abstract: Substituted and pyridines and pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R1 and R2 may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: July 12, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques P. Dumas, Stephen J. Boyer, Julie A. Dixon, Teddy K. Joe, Harold C. E. Kluender, Wendy Lee, Dhanapalan Nagarathnam, Robert N. Sibley, Ning Su
  • Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
    Patent number: 7928239
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.
    Type: Grant
    Filed: February 7, 2001
    Date of Patent: April 19, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Jill E. Wood, Robert N. Sibley, Mary-Katherine Monahan, Joel Renick, David E. Gunn, Timothy B. Lowinger, William J. Scott, Roger A. Smith
  • ?-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
    Patent number: 7897623
    Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: March 1, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Bernd Riedl, Jacques Dumas, Uday R. Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
    Publication number: 20090118268
    Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: October 10, 2008
    Publication date: May 7, 2009
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas
    Publication number: 20080194580
    Abstract: This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Application
    Filed: October 31, 2007
    Publication date: August 14, 2008
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timotthy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
    Patent number: 7371763
    Abstract: The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: May 13, 2008
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timotthy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
    Publication number: 20080108672
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: June 25, 2007
    Publication date: May 8, 2008
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
    Patent number: 7235576
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: January 11, 2002
    Date of Patent: June 26, 2007
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
    Patent number: 6903101
    Abstract: Substituted and Fused pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R1 and R2 may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: June 7, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jacques P. Dumas, Stephen James Boyer, Teddy Kite Joe, Holia N. Hatoum-Mokdad, Harold C. E. Kluender, Wendy Lee, Dhanapalan Nagarathnam, Robert N. Sibley, Ning Su
  • Substituted pyridines and pyridazines with angiogenesis inhibiting activity
    Publication number: 20040092740
    Abstract: Substituted and pyridines and pyridazines having angiogenesis inhibiting activity and the generalized structural formula 1
    Type: Application
    Filed: November 24, 2003
    Publication date: May 13, 2004
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Jacques P. Dumas, Stephen James Boyer, Julie A. Dixon, Teddy Kite Joe, Harold C. E. Kluender, Wendy Lee, Dhanapalan Nagarathnam, Robert N. Sibley, Ning Su
  • Substituted pyridines and pyridazines with angiogenesis inhibiting activity
    Patent number: 6689883
    Abstract: Substituted pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R1 and R2 may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: February 10, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jacques P. Dumas, Stephen James Boyer, Julie A. Dixon, Teddy Kite Joe, Harold C. E. Kluender, Wendy Lee, Dhanapalan Nagarathnam, Robert N. Sibley, Ning Su
  • INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS
    Publication number: 20030207914
    Abstract: This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Application
    Filed: April 19, 2002
    Publication date: November 6, 2003
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
    Publication number: 20030207872
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: January 11, 2002
    Publication date: November 6, 2003
    Applicant: BAYER CORPORATION
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
    Publication number: 20030181442
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: November 27, 2001
    Publication date: September 25, 2003
    Applicant: BAYER CORPORATION
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
    Publication number: 20030144278
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: October 30, 2002
    Publication date: July 31, 2003
    Applicant: BAYER CORPORATION
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
    Publication number: 20030105091
    Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: March 4, 2002
    Publication date: June 5, 2003
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, Scott J. William, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Naero, Joel Renick, Robert N. Sibley
  • Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
    Publication number: 20020137774
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: July 19, 2001
    Publication date: September 26, 2002
    Applicant: BAYER CORPORATION
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
    Publication number: 20020065296
    Abstract: This invention relates to the use of a group of heteroaryl ureas containing nitrogen in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: April 20, 2001
    Publication date: May 30, 2002
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timotthy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood